3 Newly Public Stocks You Wish You Bought Last Year

Just because you weren't able to get in on a hot IPO doesn't mean there aren't profits to be made once the company is actually trading on the exchange. With the help of data provided by Dealogic, TheStreet took a look at the top 3 best-performing IPOs and calculated the stock's performances based on its first day trading low to its price as of January 30th. The theme? Biopharma companies. Take Radius Health (RDUS), for example, which debuted on the Nasdaq last June. Shares of the biopharma company are up 502% from its inaugural trading day low of $8. Next up, Auspex Pharmaceuticals (ASPX). The stock is up 364% from its first-day trading low of $13.25, that's back on February 4th of last year. The company develops medicines to treat rare movement disorders. Finally, since Alder Biopharmaceuticals (ALDR), went public back in May of 2014, shares are up triple-digits - 185%. TheStreet's Scott Gamm reports from New York.